What’s Next for Bioanalytical Systems Inc (NASDAQ:BASI) After Having Less Shares Shorted?

May 17, 2018 - By Margaret Downey

Bioanalytical Systems, Inc. (NASDAQ:BASI) Logo

Investors sentiment decreased to 3 in 2017 Q4. Its down 1.00, from 4 in 2017Q3. It dived, as 1 investors sold Bioanalytical Systems, Inc. shares while 2 reduced holdings. 2 funds opened positions while 7 raised stakes. 764,480 shares or 3.48% less from 792,012 shares in 2017Q3 were reported.
Blackrock reported 0% in Bioanalytical Systems, Inc. (NASDAQ:BASI). Barclays Public Ltd Liability has invested 0% in Bioanalytical Systems, Inc. (NASDAQ:BASI). North Star Asset invested in 0% or 15,000 shares. The Massachusetts-based State Street Corp has invested 0% in Bioanalytical Systems, Inc. (NASDAQ:BASI). Acadian Asset Mgmt Limited Liability Co has invested 0% in Bioanalytical Systems, Inc. (NASDAQ:BASI). Jpmorgan Chase & has 0% invested in Bioanalytical Systems, Inc. (NASDAQ:BASI) for 100 shares. Panagora Asset Inc has invested 0% in Bioanalytical Systems, Inc. (NASDAQ:BASI). Bancorp Of America De has invested 0% in Bioanalytical Systems, Inc. (NASDAQ:BASI). Citadel Advisors Limited Liability invested in 0% or 20,886 shares. Moreover, Morgan Stanley has 0% invested in Bioanalytical Systems, Inc. (NASDAQ:BASI). Royal Financial Bank Of Canada reported 6 shares or 0% of all its holdings. Deutsche Bank & Trust Ag holds 59,400 shares or 0% of its portfolio. Virtu Finance Ltd Liability reported 32,214 shares or 0% of all its holdings. Vanguard Group Inc reported 145,008 shares or 0% of all its holdings. Renaissance Techs Limited Liability Corp accumulated 0% or 244,200 shares.

Since February 16, 2018, it had 1 buy, and 0 insider sales for $7,300 activity.

The stock of Bioanalytical Systems Inc (NASDAQ:BASI) registered a decrease of 1.61% in short interest. BASI’s total short interest was 42,800 shares in May as published by FINRA. Its down 1.61% from 43,500 shares, reported previously. With 17,600 shares average volume, it will take short sellers 2 days to cover their BASI’s short positions. The short interest to Bioanalytical Systems Inc’s float is 0.64%.

The stock decreased 0.75% or $0.0132 during the last trading session, reaching $1.7368. About 6,027 shares traded. Bioanalytical Systems, Inc. (NASDAQ:BASI) has risen 14.28% since May 17, 2017 and is uptrending. It has outperformed by 2.73% the S&P500.

Bioanalytical Systems, Inc. provides drug discovery and development services, and analytical instruments for pharmaceutical, biotechnology, academic, and government organizations in the United States, other North America, the Pacific Rim, Europe, and internationally. The company has market cap of $14.32 million. It operates in two divisions, Contract Research Services and Research Products. It has a 17.2 P/E ratio. The Contract Research Services segment offers screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance, and quality control testing services.

More recent Bioanalytical Systems, Inc. (NASDAQ:BASI) news were published by: Digitaljournal.com which released: “James Bourdage to Retire as BASi VP of Bioanalytical Operations; Michael Baim Named as Successor” on April 30, 2018. Also Streetinsider.com published the news titled: “Form 8-K BIOANALYTICAL SYSTEMS For: May 15” on May 15, 2018. Nasdaq.com‘s news article titled: “Bioanalytical Systems to Release Second Quarter Fiscal 2018 Results on Tuesday, May 15, 2018” with publication date: May 02, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: